Singapore, Dec. 22 -- South Korea-based Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has announced that its wholly owned US subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK. This strategic move secures Samsung Biologics' first US-based manufacturing site, a significant expansion of the company's global footprint and its long-term commitment to the US market.

Located in Rockville, Maryland, the facility sits at the center of one of the key US bio-clusters and encompasses two cGMP manufacturing plants with a combined 60,000 liters of drug substance capacity, supporting both clinical and commercial production from smal...